BioAtla Q2 FY26 swings to net income of $452,000; revenue rises to $6.5 million - BCAB News | RalliesBioAtla Q2 FY26 swings to net income of $452,000; revenue rises to $6.5 million
B
BCAB• Second-quarter financial results
- BioAtla posted GAAP net income of $452,000, swinging from a GAAP net loss of $18.71 million a year earlier.
- Revenue was $6.5 million, compared with no revenue a year earlier, driven by payments under the Context License Agreement amendment.
- R&D expense fell 75.58% to $3.34 million, mainly on completion of Phase 2 trials and lower personnel costs after a March 2026 workforce cut.
- G&A expense dropped 40.95% to $2.93 million, reflecting lower personnel and professional fees, partly offset by higher advisor fees.
- Cash and cash equivalents totaled $1.5 million at June 30, 2026, with management citing substantial doubt about going-concern ability.
•
